CCL2 and prostate carcinoma: Unexpectedly, the systemic administration of anti-CCL2 antibodies in prostate cancer mouse models only slightly attenuated the proliferation of tumor cells likely due to the "rescue" of the CCR2+ tumor cells by alternate chemokine ligands [27].